Editor’s cornErmAbs 5:4, 513–517; July/August 2013; © 2013 Landes Bioscience
Antibodies to watch in 2013Mid-year update
Janice M. reichert
Editor-in-chief, mAbs; Landes Bioscience; Austin, tX UsA
the transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are
proceeding at a rapid pace in 2013. since late 2012, two monoclonal antibody (mAb) therapeutics (itolizumab, trastuzumab
emtansine) received their first approvals, first marketing applications for three mAbs (vedolizumab, ramucirumab,
obinutuzumab) were submitted to regulatory agencies, and five mAbs (brodalumab, MABp1, moxetumomab pasudotox,
tildrakizumab, rilotumumab) entered their first Phase 3 studies. the current total of commercially-sponsored antibody
therapeutics undergoing evaluation in late-stage studies is 30. recently announced study results for farletuzumab,
naptumomab estafenatox, and tabalumab indicate that clinical endpoints were not met in some Phase 3 studies of these
product candidates.
Early 2013 proved to be a sufficiently busy period for anti-The parental trastuzumab was first approved in 1998 and anti-body therapeutics developers that this mid-year update to mAbs HER2 pertuzumab (PERJETA ; Genentech/Roche) was first annual coverage of antibodies in late-stage development1-4 was approved in 2012 as treatments for HER2-positive metastatic needed. A total of five antibody therapeutics (itolizumab, trastu-breast cancer. In the European Union, trastuzumab and per-zumab emtansine, vedolizumab, ramucirumab, obinutuzumab) tuzumab are approved, and trastuzumab emtansine is under-transitioned to either the market or regulatory review. Biocon going regulatory review. Trastuzumab emtansine is approved announced in January 2013 that the marketing application for patients who were previously treated with trastuzumab and for itolizumab (Alzumab) had been authorized by the Drugs taxanes. It is currently also undergoing evaluation in the Phase Controller General of India. Itolizumab is a humanized mAb that 3 MARIANNE study (NCT01120184) of trastuzumab emtan-targets CD6, which is predominantly expressed by T cells and a sine and pertuzumab vs. trastuzumab plus a taxane in patients subset of B cells. In the 52-week TREAT-PLAQ study conducted with metastatic breast cancer; the Phase 3 TH3RESA study in India, interim results indicated that patients with psoriasis area (NCT01419197) of trastuzumab emtansine compared with treat-severity index (PASI) of > 20 at baseline had PASI 75-response ment of physician’s choice in patients with HER2-positive meta-(i.e., improvement from baseline of ≥ 75%) rates of 43% and 54% static breast cancer who have received at least two prior regimens at week 12 and 28, respectively. Patients in the fixed dose treat-of HER2 directed therapy; and the Phase 3 KATHERINE study ment arm of the study received 1.6 mg/kg every two weeks for 12 (NCT01772472) of trastuzumab emtansine vs. trastuzumab as weeks followed by 1.6 mg/kg every four weeks for 16 weeks; those adjuvant therapy for patients with HER2-positive primary breast in the induction dose arm received 0.4 mg/kg every two weeks for cancer who have residual tumor present pathologically in the 12 weeks followed by 1.6 mg/kg every four weeks for 16 weeks. breast or axillary lymph nodes following preoperative therapy, Biocon is reportedly planning to launch itolizumab in India as a which was initiated in April 2013. In addition, the safety and treatment for moderate-to-severe psoriasis in the July–September efficacy of the mAb are being evaluated in an adaptive Phase 2/3 2013 quarter. The company has indicated that itolizumab has also study (NCT01641939) of patients with previously treated, locally shown promising efficacy in other autoimmune disorders, includ-advanced or metastatic HER2-positive gastric cancer, including ing rheumatoid arthritis (RA) and multiple sclerosis (MS).adenocarcinoma of the gastroesophageal junction.
n February 2013, trastuzumab emtansine (KadcylaTM; n early March 2013, Takeda Pharmaceutical Company Genentech/Roche) was approved by the US Food and Drug announced that they submitted a marketing authorization appli-Administration (FDA) as a treatment for human epidermal cation to the European Medicines Agency for vedolizumab, a gut-growth factor receptor (HER)2-positive metastatic breast cancer. selective, anti-a4b7 humanized mAb intended as a treatment for Trastuzumab emtansine is an antibody-drug conjugate (ADC) adults with moderate-to-severe active ulcerative colitis (UC) and comprising trastuzumab (Herceptin®; Genentech/Roche) linked Crohn disease (CD). The application included data from four to ImmunoGen’s DM1 maytansinoid drug. The ADC is the Phase 3 clinical studies, GEMINI I, GEMINI II, GEMINI III third anti-HER2 monoclonal antibody (mAb) on the US market. and GEMINI Long-term Safety, that evaluated the efficacy and *Correspondence to: Janice M. Reichert; Email: janice.reichert@landesbioscience.com
Submitted: 05/05/13; Accepted: 05/05/13doc.guandang.net
doc.guandang.net mAbs 513©2013 Landes Bioscience. Do not distribute.
2013年中国单克隆抗体药物市场深度调研报告_经济/市场_经管营销_专业资料。单克隆...年中国单克隆抗体药物行业产品市场价格回顾 第二节 中国单克隆抗体药物行业产品...
临床Ⅰ期与临床Ⅱ期研究 与开发的各类生物技术药物中,抗体药物的品种数量位居...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
北京智道顾问有限责任公司 2013-2017 年中国抗体药物行业现状 与发展趋势及前景预测报告 智库在线(www.zikoo.com)秉承“智通库汇 ”的服务理 念,不断收集和更新...
很大一部分抗体药物都已迈入重磅炸弹行 列,在 2008 年全球 15 大药品中,抗体...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
2013-2017年中国抗体药物市场专项调研与发展策略研究报告_经济/市场_经管营销_专业...年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2011-2012 ...
2013-2018 年中国抗体药物行业市场 运行态势及投资前景预测报告 2013-2018 年中国...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
(注:由于多用户报告的各类客户信息关 注点不同,上述所涉及的内容可根据具体需求进行调整) 2013-2018 年中国抗体药物行业市场前瞻及投资咨询报告 目录 第一章 抗体...
很大 一部分抗体药物都已迈入重磅炸弹行列,在 2008 年全球 15 大药品中,抗体...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
2013-2018年中国单克隆抗体药物行业市场行情动态及未来发展趋势预测分析报告_经济/...全球生物制药发展回顾 第二节 2012-2013 年全球生物制药产业现状综述 一、全球...
2013-2018 年中国单克隆抗体药物行 业市场监测与投资前景分析报告 2013-2018 年...全球生物制药发展回顾 第二节 2012-2013 年全球生物制药产业现状综述 一、全球...
热门文档